{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:59Z","timestamp":1787008739490,"version":"build-2736575974"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"35","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Minister for Health","award":["RF-2016-H45B16000000001"],"award-info":[{"award-number":["RF-2016-H45B16000000001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review will discuss the limitations of data collected by RCTs in relation to their applicability to daily life clinical management. It will then argue that these limitations are only partially overcome by modifications of RCT design and conduction (e.g. \u2018pragmatic trials\u2019) while being substantially attenuated by real-life-derived research, which can fill many gaps left by trial-collected evidence and have thus an important complementary value. The focus will be on the real-life research approach based on the retrospective analysis of the now widely available healthcare utilization databases (formerly known as administrative databases), which will be discussed in detail for their multiple advantages as well as challenges. Emphasis will be given to the potential of these databases to provide low-cost information over long periods on many different healthcare issues, drug therapies in particular, from the general population to clinically important subgroups, including (i) prognostic aspects of treatments implemented at the medical practice level via hospitalization and fatality data and (ii) medical practice-related phenomena such as low treatment adherence and therapeutic inertia (unsatisfactorily evaluated by RCTs). It will also be mentioned that thanks to the current availability of these data in electronic format, results can be obtained quickly, helping timely decisions under emergencies. The potential shortcomings of this approach (confounding by indication, misclassification, and selection bias) will also be discussed along with their possible minimization by suitable analytic means. Finally, examples of the contributions of studies on hypertension and other cardiovascular risk factors will be offered based on retrospective healthcare utilization databases that have provided information on real-life cardiovascular treatments unavailable via RCTs.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab899","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T15:13:22Z","timestamp":1640186002000},"page":"3312-3322","source":"Crossref","is-referenced-by-count":28,"title":["Research strategies in treatment of hypertension: value of retrospective real-life data"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-8444","authenticated-orcid":false,"given":"Giovanni","family":"Corrao","sequence":"first","affiliation":[{"name":"National Centre for Healthcare Research & Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano-Bicocca , Milan , Italy"},{"name":"Department of Statistics and Quantitative Methods, University of Milano-Bicocca , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2022102610295242700_ehab899-B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2022102610295242700_ehab899-B2","volume-title":"Effectiveness and Efficiency: Random Reflections on Health Services","author":"Cochrane","year":"1972"},{"key":"2022102610295242700_ehab899-B3","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102610295242700_ehab899-B4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","article-title":"Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals","volume":"47","author":"Okonofua","year":"2006","journal-title":"Hypertension"},{"key":"2022102610295242700_ehab899-B5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B6","doi-asserted-by":"crossref","first-page":"E1065","DOI":"10.1503\/cmaj.170107","article-title":"Finding the right balance between precision medicine and personalized care","volume":"189","author":"McAlister","year":"2017","journal-title":"CMAJ"},{"key":"2022102610295242700_ehab899-B7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacbts.2016.06.003","article-title":"Drugs and devices: comparison of European and U.S. approval processes","volume":"1","author":"Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"2022102610295242700_ehab899-B8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fphar.2018.00938","article-title":"Availability and affordability of drugs with a conditional approval by the European Medicines Agency; comparison of Korea with other countries and the implications","volume":"9","author":"Kwon","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022102610295242700_ehab899-B9","doi-asserted-by":"crossref","first-page":"j2062","DOI":"10.1136\/bmj.j2062","article-title":"Conditional approval of medicines by the EMA","volume":"357","author":"Banzi","year":"2017","journal-title":"BMJ"},{"key":"2022102610295242700_ehab899-B10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","article-title":"Explanatory and pragmatic attitudes in therapeutical trials","volume":"20","author":"Schwartz","year":"1967","journal-title":"J Chronic Dis"},{"key":"2022102610295242700_ehab899-B11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","article-title":"Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy","volume":"290","author":"Tunis","year":"2003","journal-title":"JAMA"},{"key":"2022102610295242700_ehab899-B12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.115.019902","article-title":"Good clinical practice guidance and pragmatic clinical trials: balancing the best of both worlds","volume":"133","author":"Mentz","year":"2016","journal-title":"Circulation"},{"key":"2022102610295242700_ehab899-B13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(14)70102-0","article-title":"Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment","volume":"2","author":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102610295242700_ehab899-B14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(10)62036-3","article-title":"National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5\u00b74 million participants","volume":"377","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"2022102610295242700_ehab899-B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2022102610295242700_ehab899-B16","doi-asserted-by":"crossref","first-page":"b36","DOI":"10.1136\/bmj.b36","article-title":"Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984\u20132005","volume":"338","author":"Briffa","year":"2009","journal-title":"BMJ"},{"key":"2022102610295242700_ehab899-B17","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1093\/eurheartj\/ehaa586","article-title":"Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake","volume":"41","author":"O\u2019Donnell","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102610295242700_ehab899-B18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.297.6658.1227","article-title":"Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction","volume":"297","author":"Cruickshank","year":"1988","journal-title":"BMJ"},{"key":"2022102610295242700_ehab899-B19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","article-title":"Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial","volume":"392","author":"Gupta","year":"2018","journal-title":"Lancet"},{"key":"2022102610295242700_ehab899-B21","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMp1401111","article-title":"Learning from big health care data","volume":"370","author":"Schneeweiss","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.12688\/f1000research.13585.2","article-title":"Real-world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?","volume":"7","author":"Khosla","year":"2018","journal-title":"F1000Res"},{"key":"2022102610295242700_ehab899-B23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/pubmed\/fdm065","article-title":"Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA","volume":"29","author":"Morrato","year":"2007","journal-title":"J Publ Health"},{"key":"2022102610295242700_ehab899-B24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ncprheum0652","article-title":"Primer: administrative health databases in observational studies of drug effects\u2014advantages and disadvantages","volume":"3","author":"Suissa","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2022102610295242700_ehab899-B25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/HYPERTENSIONAHA.114.04858","article-title":"Generating evidence from computerized healthcare utilization databases","volume":"65","author":"Corrao","year":"2015","journal-title":"Hypertension"},{"key":"2022102610295242700_ehab899-B26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40264-018-0732-5","article-title":"The role of European Healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand?","volume":"42","author":"Trifir\u00f2","year":"2019","journal-title":"Drug Saf"},{"key":"2022102610295242700_ehab899-B27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pupt.2018.09.009","article-title":"Building reliable evidence from real-world data: needs, methods, cautiousness and recommendations","volume":"53","author":"Corrao","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2022102610295242700_ehab899-B28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"Schneeweiss","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2022102610295242700_ehab899-B29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/cts.12559","article-title":"Innovation at the intersection of clinical trials and real-world data science to advance patient care","volume":"11","author":"Swift","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2022102610295242700_ehab899-B30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/17407745211038524","article-title":"Characteristics of available studies and dissemination of research using major clinical data sharing platforms","volume":"18","author":"Vazquez","year":"2021","journal-title":"Clin Trials"},{"key":"2022102610295242700_ehab899-B31","author":"ADR UK (Administrative Data Research UK)."},{"key":"2022102610295242700_ehab899-B32","year":"2016"},{"key":"2022102610295242700_ehab899-B33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3332\/ecancer.2017.709","article-title":"The impact of the EU general data protection regulation on scientific research","volume":"11","author":"Chassang","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"2022102610295242700_ehab899-B34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"key":"2022102610295242700_ehab899-B35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","article-title":"Methodological considerations when analysing and interpreting real-world data","volume":"59","author":"St\u00fcrmer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022102610295242700_ehab899-B36","volume-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"2022102610295242700_ehab899-B37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/oxfordjournals.aje.a008895","article-title":"Confounding by indication and channeling over time: the risks of beta 2-agonists","volume":"144","author":"Blais","year":"1996","journal-title":"Am J Epidemiol"},{"key":"2022102610295242700_ehab899-B38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2022102610295242700_ehab899-B39","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2022102610295242700_ehab899-B40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2022102610295242700_ehab899-B41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jtcvs.2007.07.021","article-title":"Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement","volume":"134","author":"Austin","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2022102610295242700_ehab899-B42","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/1475-6773.12020","article-title":"Squeezing the balloon: propensity scores and unmeasured covariate balance","volume":"48","author":"Brooks","year":"2013","journal-title":"Health Serv Res"},{"key":"2022102610295242700_ehab899-B43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/pds.4394","article-title":"Addressing unmeasured confounding in comparative observational research","volume":"27","author":"Zhang","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102610295242700_ehab899-B44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.04.022","article-title":"Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review","volume":"87","author":"Streeter","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2022102610295242700_ehab899-B45","first-page":"714","article-title":"Methods to control for unmeasured confounding in pharmacoepidemiology: an overview","volume":"38","author":"Uddin","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2022102610295242700_ehab899-B46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.ede.0000147164.11879.b5","article-title":"Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction","volume":"16","author":"Schneeweiss","year":"2005","journal-title":"Epidemiology"},{"key":"2022102610295242700_ehab899-B47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/aje\/kwh211","article-title":"Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer","volume":"160","author":"Steenland","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2022102610295242700_ehab899-B48","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jclinepi.2012.03.014","article-title":"External adjustment for unmeasured confounders improved drug-outcome association estimates based on health care utilization data","volume":"65","author":"Corrao","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2022102610295242700_ehab899-B49","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/pds.1438","article-title":"\u2018Why me?\u2019 versus \u2018why now?\u2019\u2014differences between operational hypotheses in case-control versus case-crossover studies","volume":"16","author":"Maclure","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102610295242700_ehab899-B50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0962280208092342","article-title":"The methodology of self-controlled case series studies","volume":"18","author":"Whitaker","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"2022102610295242700_ehab899-B51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jclinepi.2006.10.019","article-title":"Understanding secondary databases: a commentary on \u201cSources of bias for health state characteristics in secondary databases\u201d","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"2022102610295242700_ehab899-B52","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2022102610295242700_ehab899-B53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1357","article-title":"Immortal time bias in observational studies of drug effects","volume":"16","author":"Suissa","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022102610295242700_ehab899-B54","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"2022102610295242700_ehab899-B55","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","volume":"63","author":"Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"2022102610295242700_ehab899-B56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.200210-1231OC","article-title":"Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies","volume":"168","author":"Suissa","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2022102610295242700_ehab899-B57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-5-5","article-title":"Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure","volume":"5","author":"Essebag","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2022102610295242700_ehab899-B58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","article-title":"The problem of \u201cprotopathic bias\u201d in case-control studies","volume":"68","author":"Horwitz","year":"1980","journal-title":"Am J Med"},{"key":"2022102610295242700_ehab899-B59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.03.003","article-title":"The lag-time approach improved drug-outcome association estimates in presence of protopathic bias","volume":"78","author":"Arf\u00e8","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2022102610295242700_ehab899-B60","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cpt1971125864","article-title":"Clinical biostatistics. XI. Sources of \u2018chronology bias\u2019 in cohort statistics","volume":"12","author":"Feinstein","year":"1971","journal-title":"Clin Pharmacol Ther"},{"key":"2022102610295242700_ehab899-B61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2022102610295242700_ehab899-B62","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2022102610295242700_ehab899-B63","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","article-title":"Patient adherence and medical treatment outcomes: a meta-analysis","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med Care"},{"key":"2022102610295242700_ehab899-B64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.118.313294","article-title":"Two-drug combinations as first-step antihypertensive treatment","volume":"124","author":"Mancia","year":"2019","journal-title":"Circ Res"},{"key":"2022102610295242700_ehab899-B65","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/jch.14319","article-title":"Early adherence to antihypertensive drugs and long-term cardiovascular mortality in the \u201creal-world\u201d","volume":"23","author":"Salazar","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022102610295242700_ehab899-B66","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","article-title":"Better compliance to antihypertensive medications reduces cardiovascular risk","volume":"29","author":"Corrao","year":"2011","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B67","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.115.05463","article-title":"Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice","volume":"66","author":"Corrao","year":"2015","journal-title":"Hypertension"},{"key":"2022102610295242700_ehab899-B68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clinthera.2010.02.004","article-title":"Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy","volume":"32","author":"Corrao","year":"2010","journal-title":"Clin Ther"},{"key":"2022102610295242700_ehab899-B69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ajh.2011.261","article-title":"Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments","volume":"25","author":"Corrao","year":"2012","journal-title":"Am J Hypertens"},{"key":"2022102610295242700_ehab899-B70","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jval.2012.11.008","article-title":"Cost-effectiveness of enhancing adherence to therapy with blood pressure-lowering drugs in the setting of primary cardiovascular prevention","volume":"16","author":"Scotti","year":"2013","journal-title":"Value Health"},{"key":"2022102610295242700_ehab899-B71","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.atherosclerosis.2011.04.014","article-title":"Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases","volume":"217","author":"Corrao","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022102610295242700_ehab899-B72","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/HJH.0000000000001323","article-title":"Protective effects of antihypertensive treatment in patients aged 85 years or older","volume":"35","author":"Corrao","year":"2017","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B73","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2017.09.023","article-title":"Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real life investigation","volume":"47","author":"Corrao","year":"2018","journal-title":"Eur J Int Med"},{"key":"2022102610295242700_ehab899-B75","doi-asserted-by":"crossref","first-page":"e2113186","DOI":"10.1001\/jamanetworkopen.2021.13186","article-title":"Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy","volume":"4","author":"Rea","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022102610295242700_ehab899-B76","doi-asserted-by":"crossref","first-page":"e019503","DOI":"10.1136\/bmjopen-2017-019503","article-title":"Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy","volume":"7","author":"Corrao","year":"2017","journal-title":"BMJ Open"},{"key":"2022102610295242700_ehab899-B77","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.120.14683","article-title":"Antihypertensive treatment in elderly frail patients. Evidence from a large Italian database","volume":"76","author":"Rea","year":"2020","journal-title":"Hypertension"},{"key":"2022102610295242700_ehab899-B78","article-title":"Statin treatment reduces the risk of death among elderly frail patients: evidence from a large population-based cohort","author":"Rea","journal-title":"Eur J Prev Cardiol"},{"key":"2022102610295242700_ehab899-B79","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/HJH.0b013e3282f4edd7","article-title":"Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy","volume":"26","author":"Corrao","year":"2008","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B80","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0000000000001052","article-title":"Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B81","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/HJH.0b013e32834550d0","article-title":"Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class","volume":"29","author":"Mancia","year":"2011","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B82","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/HJH.0000000000000222","article-title":"Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data","volume":"32","author":"Mancia","year":"2014","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B83","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","article-title":"Initial antihypertensive treatment strategies and therapeutic inertia","volume":"72","author":"Rea","year":"2018","journal-title":"Hypertension"},{"key":"2022102610295242700_ehab899-B84","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ajh\/hpab083","article-title":"Adherence to treatment by initial antihypertensive mono and combination therapies","volume":"34","author":"Rea","year":"2021","journal-title":"Am J Hypertens"},{"key":"2022102610295242700_ehab899-B85","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"2018","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B86","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/eurheartj\/ehy420","article-title":"Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension","volume":"39","author":"Rea","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102610295242700_ehab899-B87","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/eci.12326","article-title":"Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study","volume":"44","author":"Corrao","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"2022102610295242700_ehab899-B88","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ejim.2014.08.002","article-title":"Are generic and brand-name statins clinically equivalent? Evidence from a real data-base","volume":"25","author":"Corrao","year":"2014","journal-title":"Eur J Intern Med"},{"key":"2022102610295242700_ehab899-B89","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/HJH.0000000000000130","article-title":"Medication persistence and the use of generic and brand-name blood pressure-lowering agents","volume":"32","author":"Corrao","year":"2014","journal-title":"J Hypertens"},{"key":"2022102610295242700_ehab899-B90","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-015-0306-5","article-title":"Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009","volume":"32","author":"Corrao","year":"2015","journal-title":"Drugs Aging"},{"key":"2022102610295242700_ehab899-B91","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B92","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102610295242700_ehab899-B93","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/HJH.0000000000002784","article-title":"Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies","volume":"39","author":"Bavishi","year":"2021","journal-title":"J Hypertens"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/35\/3312\/46642657\/ehab899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/35\/3312\/46642657\/ehab899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:48:13Z","timestamp":1666766893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/35\/3312\/6520830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":93,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab899","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,14]]},"published":{"date-parts":[[2022,2,3]]}}}